Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate efficacy and safety of Radiofrequency ablation in metastatic renal cell carcinoma patients with primary tumor less than 5 cm before medical treatment. Ablation may allow for reduced morbidity and may increase the likelihood of patients receiving systemic therapy.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kidney Cancer Research Bureau
• Treatments: Interferon-alpha; Interferons; Maleic acid; Sunitinib

Criteria

Inclusion Criteria:

• Histologically proven renal cell carcinoma before RFA;

• Primary tumor no grater than 5 cm;

• CT-confirmed metastatic measurable sites;

• Good prognosis by adapted MSKCC criteria;

• No treatment for RCC;